PURPOSE: We evaluated the utility of iopamidol-based nonionic contrast media (Pamiray(R)370) for cardiac CT, with assessment of its image quality and safety. MATERIALS AND METHODS: The study included 100 patients who underwent cardiac CT with Pamiray(R)370 (experimental group), and 100 patientswho underwent cardiac CT with Ultravist(R)370 (control group). A comparison of the image qualities and degree of vascular contrast enhancement was made between the two groups and evaluated statistically by an independent t-test. Changes in vital signs and adverse events during cardiac CT were evaluated in the experimental group. RESULTS: There were no statistically significant differences in the image quality (image quality score in experimental group vs. control group: 4.26 +/- 0.63 vs. 4.24 +/- 0.62), and mean attenuation values at the coronary arteries(p > 0.05) between two groups. For the experimental group, 12% experienced adverse events, including mild and transient reactions such as dizziness (7%), nausea (4%), and fatigue (1%). Further, 94% of patients complained of mild to moderate febrile sense just after contrast agent administration, which spontaneously disappeared within 3 minutes without any specific management. CONCLUSION: For cardiac CT, Pamiray(R)370 was comparable to the widely-used contrast agent (Ultravist(R)370) in terms of image quality and safety without any severe adverse reaction.